Interstitial deletion or loss of chromosome 5, del(5q) or 75, is a frequent ®nding in myeloid leukemias and myelodysplasias, suggesting the presence of a tumor suppressor gene within the deleted region. In our search for this gene, we identi®ed a candidate, 5qNCA (LOC51780), which lies within a consistently-deleted segment of 5q31. 5qNCA expresses a 7.2-kb transcript with a 5286-bp open reading frame which is present at high levels in heart, skeletal muscle, kidney, placenta, and liver as well as CD34+ cells and AML cell lines. 5qNCA encodes a 191-kD nuclear protein which contains a highly-conserved C-terminus containing a zinc ®nger with the unique spacing Cys-X2-Cys-X7-His-X2-Cys-X2-Cys-X4-Cys-X2-Cys and a jmjC domain, which is often found in proteins that regulate chromatin remodeling. Expression of 5qNCA in a del(5q) cell line results in suppression of clonogenic growth. Preliminary sequence results in AML and MDS samples and cell lines has revealed a possible mutation in the KG-1 cell line resulting in a THR to ALA substitution that has not been found in over 100 normal alleles to date. We propose 5qNCA is a good candidate for the del(5q) tumor suppressor gene based on its predicted function and growth suppressive activities, and suggest that further mutational and functional study of this interesting gene is warranted. Oncogene (2001) 20, 6946 ± 6954.
Introduction
Cytogenetic deletions involving chromosome 5 are frequently seen in malignant myeloid disorders, including myelodysplasia (MDS) and acute myeloid leukemia (AML). These abnormalities include complete loss of the entire chromosome [75] , loss of the long arm of chromosome 5[5q-], or interstitial deletions of the long arm [del(5q)] which usually involve multiple chromosome bands (Pedersen-Bjegaard et al., 1990; . Almost a third of MDS cases demonstrate chromosome 5 loss, including over half of those cases that occur as a late sequel of cancer chemotherapy (Pedersen-Bjegaard et al., 1990; Rowley et al., 1998; Westbrook and Le Beau, 1993; Feanaux et al., 1996) . In AML, deletions are much less frequent, but occur predominantly in high-risk patients, including the elderly, AML arising after MDS, and AML arising after chemotherapy; they are invariably associated with poor response to chemotherapy, rapid progression, and short survival (Samuels et al., 1988; Schier et al., 1989; Pedersen-Bjegaard, 1993) . Identifying the genes responsible for these syndromes will help to improve the understanding and treatment of some of the most deadly forms of AML and MDS.
The association of a chromosomal loss with a clinical malignancy suggests the presence of a tumor suppressor gene, whose mutational loss or inactivation leads to transformation. Speci®cation of a minimal deletion is the ®rst step for identi®cation of such a gene; the demonstration of the gene's inactivation by deletion and mutation is an important second step. Early studies de®ned a 4 Mb interval within 5q31 that was deleted in all patients with aggressive MDS, AML, or secondary MDS (Le Bartoloni et al., 1998; Horrigan et al., 1999) . Attempts to further re®ne the 5q31 deletion using FISH and loss of heterozygosity by ourselves (Horrigan et al., 1996 and others (Zhao et al., 1997; Frazer et al., 1997) has speci®ed two relatively small intervals, each of about 1 Mb in extent, that are immediately adjacent and located on either side of the marker D5S500. Given the uncertainties of FISH and allelic loss mapping, it is uncertain whether these intervals represent two distinct tumor suppressor genes or point to the same gene. Although a number of candidate genes have been localized to this region of 5q31, and many have compelling biology Horrigan et al., 1999; Xie et al., 2000) , none of them has been shown to meet the required criteria for a classical tumor suppressor gene: evidence for mutational inactivation in clinical samples with del(5q).
The recent release of genomic sequence for 5q31 allowed us to identify additional candidate genes and to supplement those that we have previously reported (Horrigan et al., 1999) . These resources were applied to the isolation and characterization of candidate genes.
Here we report the identi®cation and preliminary characterization of one such candidate gene, which we name`5q Nuclear Co-Activator', or`5qNCA'. We present the complete cDNA and protein sequence of this gene, demonstrate its nuclear localization and growth suppressive activity, and the identi®cation of a mutation in a del(5q) cell line. We propose that 5qNCA is a promising candidate for the tumor suppressor genes on 5q whose loss or inactivation may lead to MDS and AML.
Results

Identification of 5qNCA
Genomic sequence near the D5S500 marker was identi®ed (http://www.genome.wustl.edu/gsc/index.shtml) and searched for candidate genes. AC004821, which is known to contain the candidate genes EGR1 and SGC32445 , is just centromeric to D5S500 and was selected for further analysis. The sequence was searched for additional ESTs by BLAST search (http://www.ncbi.nlm.nih.gov) of the human EST database (dbEST, http://www.ncbi.nlm.nih.gov/ blast/). Three ESTs were identi®ed (stSG48489, N24929, stSG12690), all of which mapped to Unigene cluster #Hs.24125. The longest open reading frame in Hs.24125, named KIAA1082, was 4.7 kb in size (Figure 1a ), considerably shorter than that predicted by Northern analysis (see below). To obtain the complete sequence for the gene represented by KIAA1082, GeneScan (http://genes.mit.edu/GENSCAN.html) was used to predict additional upstream exons. This was accomplished by sequence scanning AC004821, and by comparing with genes which showed sequence homology; in particular, KIAA0742 (now known to encode the human homologs of TSGA, Testis-Speci®c Gene A). The predicted ®nal transcript size of this composite cDNA, which we have named 5qNCA, is 6.8 kb, and it contains several ATG start sites and a large open reading frame of 5286 kb ( Figure 1a ) (GenBank #AF338242); the predicted protein is given in Figure  1b .
Intron-exon boundaries were localized by alignment of the cDNA with the genomic sequence. The genomic arrangement, and its relation to other nearby genes and markers, is shown in Figure 2 . 5qNCA contains 24 exons and 23 introns and spans over 85 kb. The intron between exons 1 and 2 is the longest, being approximately 20 kb in length, while exon 8 is the longest exon, being 1.25 kb in length. All intron-exon boundary sequences contain consensus GT/AG sequences at donor and acceptor sites.
Expression of 5qNCA
An exon-connection strategy was used to con®rm that all predicted exons in the composite 5qNCA cDNA were expressed in a contiguous message. RT ± PCR was performed using primer pairs designed from the predicted sequence on normal marrow-derived cDNA. All predicted exons were con®rmed by this strategy. The sequence of the 5' predicted exons was further con®rmed by sequencing the 1.5 kb RT ± PCR product, anking exon 1 to exon 8, that was generated by primer pair S1+AS1 ( Figure 1a) ; as expected, all the cDNA sequences matched those predicted, con®rming that the expected transcript was expressed in its entirety.
While this work was in progress, additional cDNA sequences were deposited in the GenBank that are related to 5qNCA, as shown in Figure 1a . KIAA1082, the ®rst clone isolated for 5qNCA, is much shorter, and predicts the use of the most 3' ATG at position 2358, resulting in an open reading frame of 3129 bp. LOC51708 is a 6322-bp sequence that is almost identical to 5qNCA but is 390 bp shorter at the 5' end, and is also missing 96 nucleotides from exon 7, resulting in a shorter open reading frame of 4254 bp, since it utilizes the downstream ATG that corresponds to nucleotide 1135. AF25103 is identical to LOC51708, but contains an additional nucleotide at position 355, resulting in a frameshift relative to 5qNCA. AF25103 was recently reported as a gene, C5ORF7, that encodes a potential nuclear protein on 5q31 (Lai et al., 2000) . Alignment of the four cDNA sequences (Figure 1a ) suggests that they are probably derived from the same gene, with the dierences noted above. Note that the 96 additional nucleotides within exon 7 of 5qNCA are not present in AF251039 and LOC51780 and result in an additional exon boundary in AF251039 and LOC51780. The presence of these 96 nucleotides was con®rmed in all sequenced RT ± PCR products from cell lines KG-1 and HL-60 to bone marrow mononuclear cells and the cDNA from a placenta library (data not shown), as well as all genomic products of 5qNCA to date (data not shown). We have not observed a 6.3 kb mRNA transcript on Northern blots, as would be expected for both AF251039 and LOC51780. We believe that AF251039 and 5qNCA are both derived from LOC51780, but that AF251039 may be a rare splice variant. Alternatively, the clone from which AF251039 was derived may contain a sequencing error or a mutation resulting in a truncated protein and loss of expression of the 5' sequences of 5qNCA that are homologous to TSGA. The physiologic basis of this smaller transcript form remains uncertain.
5qNCA expression in normal and malignant tissues
A multiple tissue blot (Clontech, Palo Alto, CA, USA) was hybridized to a probe derived from a nonconserved region of 5qNCA (nucleotides 5120 ± 6480). As shown in Figure 3 , the gene is expressed in many tissues as a transcript of approximately 7.2 kb, with the highest levels present in the placenta, skeletal muscle, kidney, heart and liver. Two smaller transcripts are also present in placental RNA at 3 and 1.35 kb, respectively. The 1.35-kb transcript appears highlyabundant in the placenta. 5qNCA is also highly expressed in human CD34 + bone marrow cells (unpublished data). Figure 3b shows a Northern blot from three leukemia cell lines and three cancer cell 
Sequence homologies and functional motifs
As seen in Figure 4 , 5qNCA shares sequence homologies across the plant and animal kingdom. The 3' half of the ORF is highly homologous to TSGA, testis-speci®c gene A (Hoog et al., 1991) in rat, mouse, and human; TRIP8, a thyroid-hormone binding protein (Lee et al., 1995) , the human and murine hairless gene (Panteleyev et al., 1998; Cichon et al., 1998) , Drosophila CG8165, and arabidopsis/corn ENBP1. Hairless is involved in the dierentiation and apoptosis of hair follicles, but it has not been well characterized. ENBP1 is involved in plant nodule development. TRIP8 has been predicted to be a thyroid-hormone receptor co-activator. There are no known functions for TSGA or Drosophila CG8165. The three conserved motifs for all of these genes include a zinc ®nger domain ( Figure 1a , Table 1 ), a jmjC domain, and an LXXLL nuclear localization signal (Figure 1b) . The zinc ®nger demonstrates a unique C-spacing, Cys-X2-Cys-X7-His-X2-Cys-X2-Cys-X4-Cys-X2-Cys, which resembles, but is not identical to, the LIM and PHD ®ngers; this spacing is shared with TSGA, TRIP8 and ENBP1, but varies slightly from hairless. 5qNCA contains a region which is 84.7% identical to the consensus jmjC domain (Clissold and Ponting, 2001 ). This domain was ®rst described in the protein Jumonji and has since been found in over 145 proteins. Although its exact function is unclear, a common theme in jmjC containing proteins is the regulation of chromatin modeling.
The protein product of 5qNCA
To evaluate the size and cellular localization of the 5qNCA protein product, an expression vector containing the complete cDNA open reading frame was constructed in pTracer, a plasmid vector which contains the GFP marker, Zeocin resistance, and a histidine tag in-frame with the inserted cDNA. The recombinant plasmid was introduced into COS-1 cells, and positive clones were selected with Zeocin and expanded for further analysis. Protein lysate prepared from cells containing the 5qNCA expression vector was examined by Western blot using anti-His antibody, which demonstrated the presence of a 191-kD protein as the major species in three subclones examined ( Figure 5 ). This protein size correlates with that expected from the largest predicted open reading frame of 5.26 kb. To detect the cellular localization of 5qNCA, COS-1 cells expressing the gene construct were cultured on slides, ®xed, and immunostained with anti-His antibody. Fluorescent microscopy revealed that the 5qNCA-His fusion protein localized primarily to the nucleus, though a very low level of¯uorescence was observed in the cytoplasm as well ( Figure 6 ).
Growth suppressive properties of 5qNCA
To study the eects of 5qNCA on leukemic growth, the gene was introduced into the MUTZ-1 cell line, 
The conserved Cysteine or Histidine residues that comprise the Zinc-®nger motif are highlighted. Hr=hairless; Arab=Arabidopsis Oncogene 5qNCA, a candidate for the chromosome 5 tumor suppressor gene Z Hu et al which was established from a patient with MDS (Steube et al., 1997) . MUTZ-1 cells have a deletion of 5q, but express a moderate level of normal 5qNCA mRNA (see Figure 3b) . The expression vector pTracer5qNCA, or the empty vector control pTracer, were introduced into MUTZ-1 cells by electroporation. Individual Zeocin-resistant clones demonstrating GFP uorescence were picked, expanded, and further tested for clonogenic eciency, comparing them to cells transfected with empty vector. As shown in Figure 7 , constitutive expression of 5qNCA in MUTZ-1 cells in this manner signi®cantly inhibited clonogenic recovery in the transfectants. Every MUTZ-1 subclone examined showed a signi®cant decrease in colony formation varying from 30 to 80%, depending on the clone. Thus, 5qNCA has a growth suppressive eect, consistent with what might be expected of a tumor suppressor gene.
Mutation analysis of 5qNCA by genomic sequencing of AML and MDS samples 5qNCA was investigated for mutations by sequencing the complete coding region of all 24 exons in genomic DNA; three AML cell lines with chromosome 5 deletion, KG-1, HL-60, and MUTZ-1, (Furley et al., 1986; Gallagher et al., 1979; Steube et al., 1997) along with 11 clinical leukemia samples with 5q abnormalities, were studied. Primer design was based on intronic sequences and mutations were detected by comparing the resulting sequence to the wild-type 5qNCA sequence. As shown in Table 2 , four conservative nucleotide dierences were found that did not result in a change in the protein coding sequence, and represent single nucleotide polymorphisms. However, an additional sequence dierence was found in the cell line KG-1, which resulted in an amino acid substitution of threonine to alanine in codon 256 (ACG to GCG), which lies in exon 6, immediately adjacent to the 5' region that is highly conserved between 5qNCA and TSGA. This amino acid substitution was not observed in an additional 104 alleles from normal individuals, suggesting this is a very rare polymorphism or, more likely, a somatic mutation. The presence of this sequence change adjacent to a highly-conserved region suggests that it might impact on the function of the protein; whether it represents a mutational event contributing to cellular transformation will require further investigation. Overall, inactivating mutations of 5qNCA appear to be uncommon in myeloid leukemias with chromosome 5 deletions.
Discussion
Here we report the complete sequence and preliminary characterization of a novel gene, 5qNCA (LOC51780), as a candidate for the 5q31 tumor suppressor gene.
5qNCA encodes a 191-kD protein that is localized primarily to the nucleus, but its molecular function remains unknown. The protein motifs that it contains suggest an interesting biology. Almost half of the Cterminal portion of the gene is highly conserved among the plant and animal kingdoms, sharing a zinc ®nger, nuclear localization signal, nuclear coactivator motif, and a jmjC domain. All three domains are shared with hairless, ENBP1, TRIP8, TSGA, and Drosophila CG815; however, little is known about the molecular biology of any of these proteins that might shed light on the function of 5qNCA. Hairless is involved in the dierentiation and apoptosis of hair follicles (Panteleyev et al., 1998; Cichon et al., 1998; Thompson, 1996) . ENBP1 is involved in plant nodule development (Christiansen et al., 1996) . TRIP8 is a suspected thyroid-hormone receptor co-activator (Lee et al., 1995) . There are no known functions for TSGA or Drosophila CG8165, though TSGA protein contains a zinc ®nger that previously has been shown to mediate binding to nucleic acids (Hoog et al., 1991) . Recently, characterization of the jmjC domain revealed that it is shared by over 145 proteins, including many that are transcription factors or are otherwise associated with chromatin (Clissold and Ponting, 2001 ). The domain is found in metalloenzymes that adopt the cupin fold and regulate chromatin remodeling. As 5qNCA appears to be primarily a nuclear protein with a single zinc ®nger, one might speculate that it functions as a nuclear coactivator, binding other proteins that regulate cell growth or dierentiation. This gene, like the others with which it shares homology, represents an interesting and relatively unexplored category of nuclear receptor co-activators. The expression of a full-length clone of 5qNCA in COS-1 cells con®rmed that the protein is expressed primarily from the 5.2-kb open reading frame encoding a 191-kD protein, rather than the predicted 154-kD product of AF25103 (Lai et al., 2000) . The initial report of AF25103 may contain a sequence error, resulting in a frame shift that would lead to a smaller protein, leaving almost 1000 nucleotides untranslated, including 5' sequences that are homologous with TSGA, as well as the KG-1 mutation in exon 6. Our report of the complete cDNA and protein coding of 5qNCA underscores the limitations of the existing databases, particularly with regard to sequence errors, and reinforces the necessity of obtaining and con®rm-ing cDNA sequence from biological sources.
The relatively high level of expression of 5qNCA in leukemia cell lines and in normal bone marrow cells suggests that it may play an important role in the normal function of this tissue; thus, its disruption may lead to cellular transformation. To test this possibility, 5qNCA was expressed in a leukemic cell line with del(5q), resulting in signi®cantly reduced clonogenic recovery of the cells. These results suggest that constitutive expression of the protein, or correction of loss of one allele, has growth suppressive activity; thus, the activity is consistent with that of a tumor suppressor gene, and further investigation is warranted Figure 7 Eect of 5qNCA-expression on clonogenic eciency of MUTZ-1 cells. Subclone name refers to the expression vector introduced, followed by the number of a randomly-selected isolate indicated by #; MUTZ1-pTracer refers to the transfectants with empty vector. Each subclone was plated in a 96-well plate in quadruplicate and each well contains 200 cells in 100 ml of 0.8% methylcellulose growth medium with 10% FCS. Each experiment was repeated twice. The numbers of clonogenic formation in MUTZ1-pTracer, MUTZ1-5qNCA #4, #6, #15 and #18 are 78.8+3.5, 14.4+2.6, 14.6+2.5, 27.5+2.4 and 49.5+2.7, respectively. Compared to the MUTZ-1 cells transfected with the empty pTracer vector (100% clonogenic recovery), the clonogenic cell recovery in MUTZ1-5qNCA transfectants #4, #6, #15 and #18 were reduced by 79.6, 79.4, 62.2 and 30.0%, respectively In a limited screen for 5qNCA mutations, a sequence change near a highly-conserved region was found in the KG-1 cell line resulting in an amino acid substitution. The signi®cance of this missense mutation is unknown. Because KG-1 cells have already lost one chromosome 5 allele, the presence of a sequence change in the residual allele may contribute to transformation, if it results in a change in protein function; studies are underway to evaluate the functional eect of this codon change. The survey revealed many sequence polymorphisms in the other cases examined, but no nonsense or missense mutations other than that found in KG-1. We believe that it is worthwhile to search for additional mutations in more clinical AML and MDS samples, to determine if 5qNCA is a frequent target of mutational inactivation and contributes to the initiation or progression of malignant myeloid disorders.
The heterogeneity of leukemia deletion intervals along 5q suggests that there may be multiple tumor suppressor genes on this chromosome, of which 5qNCA may be one. The gene is located within the deletion interval reported by Zhao et al. (1997) , and is very close to the marker D5S500, at the boundary of an adjacent interval reported by Horrigan et al. (1999) . There are other cancer-related deletions on the long arm of chromosome 5 which might contain tumor suppressor genes; these include an interval at 5q32 which is thought to contain a gene for the more indolent 5q-MDS syndrome Nagarajan, 1995; Fairman et al., 1995) ; a segment at 5q31.1 containing IRF-1 (Willman et al., 1993) ; a site of frequent LOH in myeloid leukemias, hairy cell leukemia at 5q13 (Fairman et al., 1996) and the APC colon cancer gene located on 5q21-22 (Mao et al., 1998) . Thus, it is possible that many clinical samples with deletions target a variety of loci on 5q31, so that only a minority of cases will show mutations in a particular gene.
In summary, 5qNCA is a good candidate for a 5q tumor suppressor gene based on its predicted function, its suppressive activity, its chromosomal location, and the ®nding of a mutant allele in the KG-1 cell line. Detailed functional studies of 5qNCA, additional sequencing in clinical sample, and the eects of the sequence change found in KG-1, will be required to determine if this gene plays a role as a tumor suppressor gene or as a partner of a known tumor suppressor gene.
Materials and methods
Cell lines and clinical specimens
Cell lines used in this study were obtained from ATCC (Rockville, MD, USA) and from DSMZ (Brunschweig, Germany). Cells were cultured using recommended conditions or in RPMI-1640 medium (GIBCO BRL, Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal calf serum (Sigma, St. Louis, USA) at 378C in an atmosphere of 5% CO 2 in air. CD34 + cells were isolated from bone marrow obtained from normal donors with informed consent under the guidelines provided by the University of Illinois. The CD34 + cells were isolated and puri®ed as previously described (Brandt et al., 1999) .
Clinical specimens from MDS and AML patients containing del(5q) or 75 were obtained from patients during routine clinical treatment according to institutional IRB guidelines; all samples used were analysed for chromosome 5 loss of heterozygosity, and have been reported previously (Horrigan et al., 1996; Westbrook et al., 2000) .
PCR and reverse-transcriptase PCR (RT ± PCR)
DNA was extracted from cells using standard procedures and PCR was performed by using intron-based primers for direct genomic sequencing, as described previously . RT ± PCR was used for exon connection of 5qNCA and for cDNA cloning. RNA used for RT ± PCR was isolated from human bone marrow CD34 + cells and from leukemia cell lines using TRIzol Reagent (Gibco Technologies, Gaithersburg, MD, USA) as described previously . Exon-connection RT ± PCR was performed using the following primers: S1 (5'-aggcgggccccggcgatggcg-3')+AS2 (5'-ttggactggctccttccacttcc-3'), S2 (5'-atggtgttctagccacagagaac-3')+AS2 (5'-tctatcccttctgctagggagg-3'), S3 (5'-gacctcaaaatactacctggcc-3')+AS3 (5'-ggaccctgccagtttggattc-3'), and S4 (5'-gcggctgctgctgctgttcg-3')+AS4(5'-atgggctgagtgaggctgctggtg-3').
Northern blot analysis
Twenty mg of total cellular RNA or 3 mg of mRNA from each cell line was separated on a 1.0% formaldehyde agarose gel and transferred to Hybond-N nylon ®lters (Amersham, Arlington Heights, IL, USA), which were subsequently cross-linked with ultraviolet light. After prehybridization, the blot was hybridized to a-32 P-dCTP-labeled cDNA probe, and washed subsequently with 26SSC+0.1% SDS twice, followed by 16SSC+0.1% SDS twice, and 0.16SSC+0.1% SDS twice. The blots were exposed to X-ray ®lms with an intensifying screen at 7808C. A multiple tissue Northern blot, MTN H (Clontech, Palo Alto, CA, USA), was used to detect tissuespeci®c expression of 5qNCA. The hybridization probe was prepared from a 1360 bp fragment of human 5qNCA, which was ampli®ed by RT ± PCR using primers¯anking nucleotides 5120 ± 6480, and the probe was labeled with a-32 P-dCTP by random primer labeling using Multiprime DNA Labeling System (Amersham, Arlington Heights, IL, USA).
DNA sequencing
The DNA sequencing reaction was performed using the ABI Prism BigDye Terminator Sequencing kit (Perkin-Elmer). In brief, PCR products ampli®ed from each exon were puri®ed using Qiagen PCR puri®cation kit (Qiagen, Valencia, CA, USA). A typical 20 ml reaction containing 50 ± 90 ng DNA template from puri®ed PCR products, 0.32 mM of forward or reverse primer, and 8 ml of BigDye terminate mixture was reampli®ed as follows: 24 cycles at 968C for 30 s, annealing at 50 ± 588C (optimized for each primer pair) for 15 s, and 608C for 4 min. The reactions were puri®ed and then sequenced using an ABI prism 377 DNA sequencer (Perkin-Elmer, Norwalk, CT, USA). Analysis of the sequences was performed using SeqMan, a DNASTAR software program (DNASTAR Inc. Madison, WI, USA). 
Expression of 5qNCA
A cDNA clone of 5qNCA containing the entire 5.2-kb open reading frame was prepared by RT ± PCR from a human placenta cDNA library (Clontech, Palo Alto, CA, USA), con®rmed by sequencing and inserted into the expression vector pTracer (Invitrogen, Carlsbad, CA, USA). cDNA was inserted into the EcoRV+NotI sites in frame with a 66His-Tag. To transfer the expression vector into mammalian cells, 10 mg of puri®ed pTracer-5qNCA plasmid was transfected in to COS-1 cells by Lipofectin (GIBCO, Gaithersburg MD, USA). Forty-eight hours after transfection, cells were plated in 32-mm dishes with growth medium containing Zeocin for clone selection. Resistant clones became apparent after 2 ± 3 weeks and were examined under a¯uorescent microscope. The colonies expressing GFP were then plated in 32-mm dishes containing Zeocin for subcloning. The subclones were further con®rmed for GFP expression by¯uorescence microscopy, and positive clones were further expanded for additional study.
To evaluate whether 5qNCA has growth suppressive properties, the expression vector pTracer-5qNCA was introduced into MUTZ-1 cells, an MDS cell line with 5q deletion, by electroporation at 250 V and 950 mFD. 24 h after electroporation, the transfectants were selected in 800 mg/ml of Zeocin for clone selection, followed by isolation of individual positive clones in 0.8% methylcellulose. Zeocinresistant clones, which contain GFP¯uorescence were picked, expanded, and analysed by¯ow¯uorescence-activated¯ow cytometry (FACS) and by Western blot to con®rm the expression of 5qNCA-His protein. The selected positive clones were further tested for clonogenic eciency by plating the cells in 0.8% methylcellulose culture.
Western blot
For protein extraction, 5610 6 COS-1 cells were suspended in lysis buer for 1 h at 48C with freshly added protease inhibitors. The nuclei were removed by centrifugation. One hundred mg of protein from each sample was solubilized with SDS-polyacrylamide gel electrophoresis (SDS ± PAGE) sample buer, and electrophoresed through 8% SDSpolyacrylamide gel for about 2 h at room temperature. For immunobloting, the proteins separated by SDS ± PAGE were electrotransferred onto nitrocellulose ®lters (Amersham, Arlington Heights, IL, USA). The ®lters with the proteins were incubated with primary antibody (His-Probe) against histine (Santa Cruz, CA, USA) for 2 h and were then incubated with HRP-labeled secondary antibodies for another hour and subsequently developed using ECL detection systems (Amersham, Arlington Heights, IL, USA).
Subcellular localization of 5qNCA-His fusion protein COS-1 clones expressing GFP were grown on coverslides in tissue culture plates for 24 h. The coverslides were subsequently washed three times with PBS, followed by ®xation in 4% formaldehyde in PBS for 20 min and then in pre-cold acetone for 30 s. After blocking by 1% BSA in PBS for 20 min, the slides were incubated with primary antibody Hisprobe (Santa Cruz, CA, USA) for 3 h, followed by incubation with secondary antibody labeled with TRITC (Sigma, St. Louis, USA) for 1 h. The slides were washed with PBS, and the cellular localization of 5qNCA-His fusion protein was evaluated under a¯uorescent microscope with a 630 nm wavelength.
Clonogenic Assay
The clonogenic assay was performed to evaluate the eect of 5qNCA on clonogenic recovery of leukemia cells as previously described . Brie¯y, clonogenic cells were detected by their capacity to give rise to colonies when plated in 0.8% methylcellulose with RPMI-1640 plus 10% FCS (growth medium) in a micro-well plate (Linbro, Flow Lab, Mclean, VA, USA), after plating 200 cells/well. Colonies containing more than 20 cells were counted after 5 ± 7 days using an inverted microscope.
